LONG-TERM OUTCOMES FOLLOWING A SWITCH FROM ORIGINATOR ADALIMUMAB TO THE BIOSIMILAR SB5 (IMRALDI) IN IBD

Heather Dolby  1     Laura Lucaciu  1     Caitlin Rees  1     Mathew Lyons  1     Lauranne Derikx  1     Nikolas Plevris  1     Shanna Su  2     Claire O'Hare     Laura Kirkpatrick     Lynne Merchant     Ian D Arnott     Nathan Constantine-Cook     Spyridon (Spyros) Siakavellas     Colin Noble     Philip Jenkinson     Gareth R Jones     Charlie Lees    
1 Western General Hospital,Edinburgh,United Kingdom
2 Western General Hospital,Edin

Session
IBD (Posters)

Citation
United European Gastroenterology Journal 2021; 9 (Supplement 1)


Login to access library content

Login

Do you need help setting up your myUEG account?
Contact us at [email protected]

New to myUEG?

Create myUEG account

Forgot your password?

Reset myUEG password

Social Sharing